Armata Pharmaceuticals (ARMP) director receives 51,280 stock options at $12.92

Rhea-AI Filing Summary

Armata Pharmaceuticals director Daniel B. Gilmer received a grant of stock options for 51,280 shares of common stock. The options have an exercise price of $12.92 per share and expire on April 24, 2036.

According to the terms, one-third of the underlying shares vest on each of the first, second, and third anniversaries of the April 24, 2026 grant date, as long as Gilmer continues to provide service through each vesting date. After this grant, he holds 51,280 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gilmer Daniel B.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	51,280	$0.00	--

Holdings After Transaction: Stock Options (Right to Buy) — 51,280 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 51,280 options Exercise price: $12.92 per share Expiration date: April 24, 2036 +2 more

5 metrics

Options granted 51,280 options Stock options on common stock granted to director

Exercise price $12.92 per share Strike price for the granted stock options

Expiration date April 24, 2036 Options expire on this date

Post-grant option holdings 51,280 options Total options held directly after this grant

Vesting pattern 1/3 annually over 3 years Subject to continuous service through each vesting date

Key Terms

Stock Options (Right to Buy), exercise price, vesting, expiration date, +1 more

5 terms

Stock Options (Right to Buy) financial

"security_title": "Stock Options (Right to Buy)""

exercise price financial

"conversion_or_exercise_price": "12.9200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The Stock Option vests as to one-third of the underlying shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date": "2036-04-24T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gilmer Daniel B.

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CALIFORNIA 90066

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$12.92	04/24/2026		A		51,280		(1)	04/24/2036	Common Stock	51,280	$0.00	51,280	D

Explanation of Responses:

1. The Stock Option vests as to one-third of the underlying shares of common stock on each of the first, second and third annual anniversaries of the date of grant, subject to continuous service through the vesting date.

	/s/ Daniel Gilmer	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Armata Pharmaceuticals (ARMP) report for Daniel B. Gilmer?

Armata Pharmaceuticals reported that director Daniel B. Gilmer received a grant of stock options for 51,280 shares of common stock. These options are a form of equity compensation, not an open-market purchase, and give him the right to buy shares at a fixed price.

What is the exercise price of Daniel B. Gilmer’s new Armata Pharmaceuticals (ARMP) stock options?

The stock options granted to Daniel B. Gilmer have an exercise price of $12.92 per share. This is the fixed price at which he can buy Armata common stock if and when the options vest and he chooses to exercise them.

How do the newly granted Armata Pharmaceuticals (ARMP) options to Daniel B. Gilmer vest?

The options vest in three equal annual installments. One-third of the 51,280 underlying common shares vest on each of the first, second, and third anniversaries of the April 24, 2026 grant date, provided Gilmer continues in service through each vesting date.

When do Daniel B. Gilmer’s Armata Pharmaceuticals (ARMP) stock options expire?

The stock options granted to Daniel B. Gilmer expire on April 24, 2036. After this expiration date, any unexercised options will lapse, meaning he would no longer have the right to buy Armata common stock at the $12.92 exercise price.

How many Armata Pharmaceuticals (ARMP) options does Daniel B. Gilmer hold after this grant?

Following the reported grant, Daniel B. Gilmer holds 51,280 stock options directly. Each option represents the right to acquire one share of Armata common stock at the stated exercise price, subject to the vesting schedule and the stated expiration date.